Transcending undruggable targets via new pathway modulation

Session Chair(s)

• 

  Allison Olszewski, PhD

  Senior Director, Lead Discovery
  Triana Biomedicines, Massachusetts, United States

Presentations:

• 1:00 PM – 1:30 PM

  Accelerating the validation of endogenous on-target engagement and assessment of in-cellulo kinetics for covalent inhibitors in early drug discovery
  

  Vasudev Kantae, PhD – AstraZeneca
• 1:30 PM – 2:00 PM

  Predicting small molecule target tractability to prioritize and accelerate hit ID activities
  

  Christopher Dimitri, PhD – NCE Molecular Discovery - GlaxoSmithKline
• 2:00 PM – 2:30 PM

  RNA Modifying Protein (RMP) Targeted Cancer Drug Discovery
  

  Shane Buker, PhD – Accent Therapeutics